Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China

Fineline Cube Mar 30, 2026
Company Deals

China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio

Fineline Cube Mar 30, 2026
Company Deals

Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic

Fineline Cube Mar 30, 2026
Company Deals

Novartis to Acquire Excellergy for Up to $2 Billion, Adding Next-Gen Anti-IgE Antibody Exl-111 to Immunology Pipeline

Fineline Cube Mar 30, 2026
Company Deals

Huahai Pharma and Almirall Strike $340M Monoclonal Antibody Licensing Deal Targeting Dermatology and Beyond

Fineline Cube Mar 30, 2026
Policy / Regulatory

China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years

Fineline Cube Mar 26, 2026
Company Drug

Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise

Fineline Cube Mar 30, 2026
Company Drug

Huadong Medicine’s YY001 Becomes World’s First Recombinant Botulinum Toxin Approved in China for Glabellar Lines

Fineline Cube Mar 30, 2026
Company Drug

JW Therapeutics Initiates Clinical Study for Carteyva in First-Line High-Risk Large B-Cell Lymphoma

Fineline Cube Mar 9, 2023

China-based JW Therapeutics (HKG: 2126) has announced the initiation of a clinical study for its...

Company Deals

Evaheart Med Raises USD 100 Million in Series A Funding Led by Sinovac

Fineline Cube Mar 9, 2023

Chongqing Evaheart Medical Device Co., Ltd has reportedly raised close to USD 100 million in...

Company Deals

HQ Pharma and Shanxi HCXF Partner to Expand Oral Soluble Film R&D and Production

Fineline Cube Mar 9, 2023

China-based firms HQ Pharma and Shanxi HCXF Pharmaceutical Co., Ltd have agreed to jointly expand...

Company Deals

Biocytogen and Janssen Sign Licensing Agreement for RenLite Platform

Fineline Cube Mar 9, 2023

Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the signing of a non-exclusive licensing...

Company Deals

Sumitomo Pharma Secures Rights to Vibegron for Asian Markets

Fineline Cube Mar 8, 2023

Japan-based Sumitomo Pharma Co., Ltd has signed a sub-license deal with compatriot firm Kyorin Pharmaceutical...

Company Deals

Suzhou Porton Biologics Partners with Bennu Biotherapeutics for Gene and Cell Therapies

Fineline Cube Mar 8, 2023

China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has entered into a...

Company Deals

Akeso Biopharma and Shanghai Pharmaceuticals Collaborate on Liposarcoma Treatment

Fineline Cube Mar 8, 2023

China-based Akeso Biopharma (HKG: 9926) has announced a strategic collaboration agreement with compatriot firm Shanghai...

Company Deals

F-star Therapeutics’ Acquisition by invoX Pharma Cleared by CFIUS

Fineline Cube Mar 8, 2023

UK biotech F-star Therapeutics, Inc. (NASDAQ: FSTX) has announced that it has received clearance from...

Company Drug

Biocytogen’s YH008 Gets NMPA Approval for Phase I Study

Fineline Cube Mar 8, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced receiving approval from the China National Medical...

Company Deals

Heranova Closes $10M Seed Round for Women’s Health Solutions

Fineline Cube Mar 8, 2023

Heranova Lifesciences Holding, a provider of women’s health solutions, has announced the successful closure of...

Company Drug

Inmagene’s Tavalisse First Prescribed in China for ITP Treatment

Fineline Cube Mar 8, 2023

China-based Inmagene Biopharmaceuticals has announced that its in-licensed drug Tavalisse (fostamatinib) has been first prescribed...

Company Drug

AusperBio Initiates Phase I Trial for AHB-137 in New Zealand

Fineline Cube Mar 8, 2023

Sino-US liver therapy developer AusperBio has announced the initiation of the first cohort dosing in...

Policy / Regulatory

China’s Party and State Institutions Reshuffle: Key Changes for Healthcare and Finance

Fineline Cube Mar 8, 2023

The second plenary session of the 20th Communist Party of China (CPC) Central Committee has...

Company Drug

BrightGene’s Generic Halaven Approved for Marketing in China

Fineline Cube Mar 7, 2023

China-based BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166) has received marketing approval from the National...

Company Deals

Abcam and MEDx Expand Strategic Partnership on Claudin 18.2 Diagnosis

Fineline Cube Mar 7, 2023

UK-based abcam (NASDAQ:ABCM) has announced a licensing agreement with China-headquartered MEDx Translational Medicine Co., Ltd,...

Company Drug

Inovio and ApolloBio Announce Positive Phase III Data for VGX-3100 Vaccine

Fineline Cube Mar 7, 2023

US-based Inovio Pharmaceuticals (NASDAQ: INO) and China-based ApolloBio Corp. (NEEQ:430187) have announced positive data from...

Policy / Regulatory

Sunshine Medical Procurement Platform Announces VBP Tender Results for Yangtze River Delta

Fineline Cube Mar 7, 2023

Shanghai’s Sunshine Medical Procurement All-In-One (SMPA) platform has revealed the resultant winning bids and spare...

Company Deals

Neo Modulus Secures Series B Funding for Regenerative Medical Device Development

Fineline Cube Mar 7, 2023

Neo Modulus, a developer of regenerative implantable medical devices based in Suzhou, has reportedly raised...

Company Drug

Takeda’s Exkivity Receives First Prescription in China with Innovative Payment Solutions

Fineline Cube Mar 7, 2023

Takeda Pharmaceutical Co., Ltd has announced the first prescription of its lung cancer therapy Exkivity...

Policy / Regulatory R&D

Pudong New Area Grants Duty-Free Import Qualifications to Seven Companies

Fineline Cube Mar 7, 2023

Seven companies have been awarded scientific and technological innovation duty-free import qualification designations by the...

Posts pagination

1 … 531 532 533 … 643

Recent updates

  • Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China
  • China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio
  • Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise
  • Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic
  • Huadong Medicine’s YY001 Becomes World’s First Recombinant Botulinum Toxin Approved in China for Glabellar Lines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China

Company Deals

China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio

Company Drug

Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise

Company Deals

Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.